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Gaucher disease is a sphingolipidosis that leads to an accumulation of glucosylceramide. The objective 
of this study was to develop a methodology, based on the extraction, purification and quantification 
of glucosylceramide from blood plasma, for use in clinical research laboratories. Comparison of the 
glucosylceramide content in plasma from Gaucher disease patients, submitted to enzyme replacement 
therapy or otherwise, against that from normal individuals was also carried out. The glucosylceramide, 
separated from other glycosphingolipids by high performance thin layer chromatography (HPTLC) 
was chemically developed (CuSO4 / H3PO4) and the respective band confirmed by immunostaining 
(human anti-glucosylceramide antibody / peroxidase-conjugated secondary antibody). Chromatogram 
quantification by densitometry demonstrated that the glucosylceramide content in Gaucher disease patients 
was seventeen times higher than that in normal individuals, and seven times higher than that in patients 
on enzyme replacement therapy. The results obtained indicate that the methodology established can be 
used in complementary diagnosis and for treatment monitoring of Gaucher disease patients. 
Uniterms: Glucosylceramide. Blood plasma analysis. Gaucher disease.
A doença de Gaucher é uma esfingolipidose caracterizada pelo acúmulo de glicosilceramida. O 
objetivo deste estudo foi desenvolver metodologia baseada na extração, purificação e quantificação 
da glicosilceramida plasmática a qual possa ser usada em laboratórios de pesquisa clínica. Após o 
desenvolvimento desta metodologia, foi proposto, também, comparar o conteúdo de glicosilceramida 
presente no plasma de pacientes com doença de Gaucher, submetidos ou não a tratamento, com aquele 
de indivíduos normais. A glicosilceramida, separada de outros glicoesfingolipídios por cromatografia 
de camada delgada de alto desempenho (HPTLC), foi revelada quimicamente (CuSO4/H3PO4) e a 
respectiva banda foi confirmada por imunorrevelação (anticorpo anti-glicosilceramida humana/anticorpo 
secundário conjudado à peroxidase). A quantificação do cromatograma por densitometria demonstrou 
que o conteúdo de glicosilceramida nos pacientes com doença de Gaucher era 17 vezes maior que aquele 
de indivíduos normais e 7 vezes maior que aquele dos pacientes com doença de Gaucher submetidos a 
tratamento com terapia de reposição enzimática. Os resultados obtidos demonstram que a metodologia 
estabelecida pode ser usada como diagnóstico complementar e como monitoração do tratamento de 
pacientes com doença de Gaucher.
Unitermos: Glicosilceramida. Análise plasmática. Doença de Gaucher.
INTRODUCTION
Gaucher Disease (GD) is a sphingolipidosis caused 
by a disorder in the metabolism of glycosphingolipids 
due to a recessive autosomal mutation in the gene of the 
acid beta-glucosidase (β-glu) enzyme. This defect results 
in the progressive storage of glucosylceramide (GluCer) 
in the cells of the mononuclear phagocyte system, which 
are then called Gaucher cells (Beutler, Grabowski, 2001; 
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Fost et al., 2003; Futerman et al., 2004; Moyses, 2003). 
Three different phenotypes are recognized based on the 
presence (types 2 and 3) or absence (type 1) of neurolo-
gical involvement. Gaucher Disease Type 1, defined as 
non-neuropathic, is the most common and occurs in about 
99% of diagnosed cases (Aerts et al., 2003; Jakóbkiewicz-
Banecka et al., 2007). 
Treatment of GD is based on enzyme replacement 
therapy (ERT) and, more recently, on substrate reduc-
tion therapy (SRT) (Aerts et al., 2003; Brady, 2003; 
Jakóbkiewicz-Banecka et al., 2007). In ERT the recombi-
nant enzyme imiglucerase replaces the defective enzyme 
and splits the accumulated glucocerebroside, while in SRT 
a small molecule, miglustat (N-butyldeoxynojirimycin), 
inhibits the synthesis of substrates accumulated in GD. 
This guarantees that the residual activity of the mutant 
enzyme is sufficient to avoid the formation of pathologi-
cal storage (Germain, 2004; Hollak et al., 1994; Zimran, 
Elstein, 2003).
The methods used to confirm the diagnosis of GD 
are (i) determination of b-glu activity and (ii) molecular 
characterization (Beutler, Grabowski, 2001; Fost et al., 
2003; Guo et al., 1995; Wajner et al., 2007). Although 
chitotriosidase (CT) is often used as a biomarker in GD, 
mainly in treatment monitoring, Moyses (2003) and Aerts 
et al (2003) stated that elevated enzyme activity is not a 
condition specific to this pathology. It has been demonstra-
ted that a mutation in the CT gene, consisting of a duplica-
tion of 24 base pairs in exon 10, causes a deficiency of CT 
activity in 6% of the world’s population, which invalidates 
its use as a specific biomarker (Guo et al., 1995; Hollak 
et al., 1994). In view of this scenario, it is clear that other 
biomarkers are necessary.
The quantification of glucosylceramide (GluCer) 
accumulated in GD is a strong candidate as a biomarker 
for this pathology (Gornati et al., 1998). However, it is 
not widely used in practical biochemistry because of the 
difficulties in the quantification methods. According to 
Groener et al. (2007), the quantification of GluCer by mass 
spectrometry is highly laborious and costly, and requires 
sophisticated equipment and specialized operators. These 
same authors suggest that GluCer could be quantified by 
HPLC (High performance liquid chromatography), but 
this technique also requires sophisticated and costly equi-
pment, which is not always available to clinical analyses 
laboratories.
In this study, we proposed a methodology for GluCer 
evaluation that can be carried out in clinical laboratories. It 
is based on the extraction and purification of this glycos-
phingolipid from blood plasma, with the subsequent quan-
tification by densitometry of the GluCer band separated 
by HPTLC. We also compared the GluCer content from 
plasma of GD patients submitted to ERT or otherwise, with 
that of normal individuals.
MATERIAL AND METHODS
Samples
Peripheral venal blood (5 mL) was collected from 
15 individuals using heparinized syringes. Blood plasma 
was separated by centrifugation at 600 x g for 10 minutes 
and stored at -40 °C until required. The samples of normal 
individuals (n = 5) came from a blood bank supplied by 
voluntary donors, while the samples of individuals with 
GD (n = 10) were collected from patients diagnosed in the 
Genetic Medical Service of the Hospital de Clinicas de 
Porto Alegre (HCPA), Rio Grande do Sul, Brazil according 
to β-glucosidase activity. β-glucosidase activity in all GD 
patients was between 0 and 5 nmol/h/mg of protein (nor-
mal values are between 10 and 45 nmol/h/mg of protein). 
The study was conducted in conformity with the Helsinki 
Declaration of the World Medical Association and was 
approved by the Committee of Ethics of HCPA. All the 
participating individuals signed an informed consent. 
Methods
Figure 1 shows a flow chart of the methodology 
used in this study. This methodology will be described in 
detail below.
Total lipid extraction
Total lipids were extracted according to Doering et 
al (1999) with the modifications required to use plasma 
samples. Plasma (600 mL) of each individual was sequen-
tially treated with chloroform: methanol (C:M) mixtures 
in the proportions of 1:2 (1800 mL), 1:1 (1200 mL) and 2:1 
(1800 mL), at 37 ºC, for 2 hours under constant shaking. 
These three extracts were mixed and solvent mixtures 
evaporated. The dry residue obtained was denominated 
total lipid extract.
Purification and isolation of GluCer
Silicic acid column (Sigma-Aldrich, Saint Louis, 
MO, USA): the total lipid extract residue was suspended 
in 1 mL of chloroform (C)/methanol (M) (98:2) mixture 
and submitted to a silicic acid (500 mg) column according 
to Ullman and McCluer (1977). The C/M (98:2) eluate 
(apolar fraction) (2000 µL) was discarded. The acetone 
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(A)/methanol (M) (9:1) eluate (polar fraction) (2000 µL) 
was evaporated and the dry residue was submitted to gentle 
alkaline methanolysis. 
Alkaline methanolysis: The dry residue of the A/M 
(9:1) fraction obtained from the silicic acid column was 
suspended in 1 mL of a 0.6 N NaOH methanolic solution 
and incubated for 90 minutes at 37 ºC, as described by 
Ullman and Mc Cluer (1977). This procedure hydrolyzes 
phosphoglycerolipids, but not glycosphingolipids. 
Sep-pack® with C18 cartridges column (Waters, 
Milford, MA, USA): The material obtained by alkaline 
methanolysis was evaporated under nitrogen gas flow. 
The residue was suspended in C:M (1:1) (1000 µL) and 
submitted to the Sep-Pack® column (65 mg) to eliminate 
salts and low molecular mass compounds and purify 
glycosphingolipids (Williams and McCluer, 1980). Two 
eluates of C/M/water (3:48:47) (3000 µL) and (60:30:4.5) 
FIGURE 1 - Flow-chart of methodology used. Details are 
described in the text.
(1600 µL) were collected from the Sep-Pack® column and 
stored as a pool. This purified material was evaporated 
under nitrogen gas flow at 37 ºC and the residue analyzed 
by chromatography.
Analysis by High Performance Thin Layer 
Chromatography (HPTLC)
The purified glycosphingolipid fraction was analyzed 
by HPTLC (Silica Gel 60 A, 20 x 10 cm plates, Merck, 
Darmstadt, Germany). In order to allow application, each 
residue was suspended in 50 µL of C/M (1:1). Two solvent 
systems were used, according to Tani-ichi et al (2005). The 
first consisted of C/M/water (65:25:4), and the second of 
hexane/ethylic ether/acetic acid (50:50:1). The chromato-
gram was visualized by spraying with 10% CuSO4 and 8% 
H3PO4 in water, and heating at 150 °C (Doering et al., 1999). 
GluCer (Sigma-Aldrich, Saint Louis, MO, USA) was used 
as the standard. GluCer was quantified by densitometry 
scanning of the chromatogram with a CS 930 Shimadzu 
UV/vis densitometer. These results were compared with a 
chromatogram obtained from known quantities of GluCer, 
according to Gonarti et al. (2002). We measured recove-
ries of GluCer by standard addition of this lipid to normal 
plasma. The amount of GluCer was a linear function of the 
amounts added, and recovery was about 11.2%. 
The linearity of GluCer quantification is shown in 
Figure 2 (r = 0.98). These data were obtained by den-
sitometric scanning of standard GluCer content after 
chromatographic performance. The intra-assay CV (n=6) 
measured in control and GD plasma was <5.3% for Glu-
Cer. The inter-assay CV (n=6) was <9%. 
Protein quantification
The proteins were determined from each plas-
FIGURE 2 - Linearity of GluCer measurement in plasma. Area 
determined by densitometric scanning of GluCer band from 
chromatogram. 
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ma sample by the Biuret method according to the 
manufacturer’s instructions (Biuret Reagent – total pro-
teins, Labtest, Lagoa Santa, MG, Brazil) and described by 
Gornal et al. (1949). 
HPTLC-Immunostaining
The confirmation of the GluCer band identity was 
carried out by immunostaining using the procedure des-
cribed by Brade et al. (2000) with modifications for the 
blocking buffer (Haycock 2003). The immunostaining 
was started by chromatogram incubation in a blocking 
buffer (50mM Tris-HCl pH 7.4; 200 mM NaCl; 0.1% 
Polyvinylpyrrolidone, Sigma-Aldrich, Saint Louis, MO, 
USA) for two hours at 24 ºC with gentle shaking. Subse-
quently, the chromatogram was incubated with the primary 
antibody (human anti-glucosylceramide rabbit antibody) 
(Glyco-Tech Produktions und Handelsgesellschaft mbH, 
Kuelkels, Germany) diluted to 1:500 in a washing buffer 
(50 mM Tris-HCl pH 7.4; 200 mM NaCl) for four hours 
at 24 ºC with gentle shaking. 
After five washes with the washing buffer, the 
chromatogram was incubated with peroxidase-conjugated 
goat anti-rabbit immunoglobulin (IgG) (heavy and light 
chain specific, Dianova, Sigma- Aldrich, Saint Louis, MO, 
USA), diluted in a washing buffer (1:1000) for two hours, 
at 24 °C with gentle shaking. Next, four washes as descri-
bed above were performed and a fifth wash was conducted 
with the substrate buffer (0.1 M sodium citrate, pH 4.5). 
Bound antibody was then detected by incubation 
of the chromatogram for 30 minutes at 24 ºC in a freshly 
prepared substrate solution (10 mL) composed of 8.33 mL 
of substrate buffer; 1.6 mL 4-chloro-1-naphthol (3 mg/mL 
in MeOH) and hydrogen peroxide (3.3 mL in a 30% so-
lution) (Haycock, 2003). The immunoassay results are 
shown in Figure 3B, lines 1b, 2b and 3b. 
FIGURE 3 - Analysis by HPTLC of purified lipid extracts of plasmas obtained from GD patients on ERT or otherwise, and normal 
individuals. Band 1 (––), band 2 ( ). A. Processing in CuSO4 10%/H3PO4 8% (lines 1, 2 and 3 correspond to the GluCer standard 
0.25 mg, 0.5 mg and 1.5 mg, respectively). Lines 4, 5 and 7 refer to GD patients without treatment while lines 6 and 8 represent GD 
patients on ERT. Lines 9 and 10 represent samples from normal individuals. B. Immunoprocessing (1b standard GluCer 0.5 mg; 
2b GD patient without treatment and 3b normal individual). 
Statistical analysis
To determine significant differences between groups 
(p<0.05) the one-way ANOVA was applied followed by 
the Tukey test, when necessary. The tests were conducted 
using the SPSS-PC version 12 software package.
RESULTS
The methodology used in this study allowed extrac-
tion (C/M), purification (Silicic Acid Column, Methanoly-
sis and Sep-Pack column), separation and detection (HP-
TLC with chemical developing) of GluCer in the plasma of 
GD patients receiving ERT or otherwise, as well as GluCer 
of normal individuals (Figure 3A, band 1). The presence 
of GluCer (band 1) in the chromatogram was confirmed 
by immunostaining with human anti-glucosylceramide 
(primary antibody), followed by goat anti-rabbit immuno-
globulin (secondary antibody) conjugated with peroxidase 
(Figure 3B, lines 1b and 2b). This band was detected only 
in the subjects from lines 4, 5 and 7 (Figure 3A), GD pa-
tients without treatment. 
Figure 3A, lines 4, 5, 6, 7, 8, 9 and 10, shows another 
band (band 2) with migration velocity slightly higher than 
GluCer standard (band 1), with similar content in all sam-
ples. Band 2 was also immunostained (Figure 3B). This 
band could be another glucocerebroside with a different 
sphingoid chain that is present in all individuals.
Table I shows the GluCer concentrations (GluCer 
content ratio obtained by densitometric analysis and 
plasma volume or protein content). The data confirmed 
previous findings, that is, the concentration of GluCer ex-
pressed in different units is significantly higher (p<0.001) 
in GD patients not receiving treatment compared to normal 
individuals or to GD patients being treated with ERT. 
There was no significant difference between the plasmatic 
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GluCer levels of normal individuals compared to those of 
GD patients on treatment. 
DISCUSSION
Gaucher Disease is the most common lysosomal 
storage disease. It is an autosomal recessive disorder 
caused by a deficiency in β-glu enzyme that leads to 
an accumulation of GluCer in the lysosomes, mainly in 
cells of the reticuloendothelial system. The present study 
described a methodology to extract, purify and quantify 
GluCer in plasma of GD patients, and compared these 
results with those of normal individuals. In addition, the 
quantity of GluCer of patients with GD receiving treatment 
was compared with that of patients who were not in use of 
any form of treatment. 
The procedures described in this study are simple 
to apply and are economically viable for use in clinical 
analysis laboratories, where equipment required to work 
with different glycosphingolipids is not always available, 
such as mass spectrometer (Groener et al., 2007; Whitfield 
et al., 2002) and HPLC (Ullman, McCluer, 1977). The 
technology tested in this study can be applied simulta-
neously to a considerable number of samples. Also, the 
method devised is advantageous compared with earlier 
thin-layer approaches (Vance, Sweeley, 1967) because it 
was standardized for a small sample volume. 
The results presented in Figure 3 and Table I de-
monstrate an increased plasmatic GluCer level of GD 
patients not receiving treatment (lines 4, 5 and 7) while 
the plasmatic GluCer levels of normal individuals (lines 9 
and 10) and patients undergoing treatment by ERT (lines 
6 and 8) are shown to be similar. All groups demonstrated 
the same behavior discussed in the literature (Gornati et 
al., 2002; Ullman, McCluer, 1977; Vance, Sweeley, 1967). 
Some authors have noted that the glucosylcerami-
de levels in GD patients might show variations both in 
concentration and in distribution percentage, as a conse-
quence of the mobility of GluCer between the plasmatic 
and erythrocyte lipoproteins and white blood cells (van 
den Bergh, Tager, 1976; G. Dawson, Oh, 1977). This fact 
suggests that alterations in the components of the blood 
such as erythrocytes and platelets can modify the plas-
matic distribution pattern of glycolipids. In the present 
paper, plasmatic GluCer levels of GD patients without 
treatment were some 17 times higher than those of normal 
individuals. 
According to Whitfeld et al. (2002), mean plasmatic 
GluCer levels of GD patients was 16.3 mmol/L, while in 
normal individuals the value was 7.4 mmol/L. In Groener 
et al. (2008), GluCer concentration in non-treated patients 
was observed to vary between 6.5 and 45.5 nmol/mL 
(mean = 17.5 nmol/mL), while for the control group varied 
between 4.0 and 8.6 nmol/mL (mean = 5.9 nmol/mL). 
Our results showed a mean plasmatic GluCer level 
of 1.31 mmol/L for GD individuals without ERT versus 
0.07 mmol/L for healthy individuals. In spite of the fact 
that these values are 10 times lower than those found by 
Whitfeld et al. (2002) and that the recovery of GluCer 
was about 11.2%, the methodology described in this study 
observed a considerable difference between the groups 
studied. Some detection methods are known to determine 
lower GluCer quantities (Groener et al., 2007). Never-
theless, we emphasize that the method described in the 
present paper allowed the detection of differences between 
controls and GD patients with and without ERT treatment. 
The method developed in the present study did 
not reveal overlapping GluCer levels between healthy 
individuals and GD patients (0 to 0.15 µmol/L and 0.44 
to 1.76 µmol/L, respectively). By contrast, overlapping 
GluCer concentration was indeed observed in a study that 
employed mass spectrometry to compare GluCer levels 
between GD patients (0.2 to 54.2 µmol/L) and healthy 
individuals (3.7 to 14.7 µmol/L) (Ghauharali-van der 
Vlugt et al., 2008). 
According to Meikle et al. (2008), the lipid analysis 
in GD may be used to monitor the therapy and correlate 
it with the severity of the disease. This approach was cor-
roborated by the findings of our study, as GD individuals 
on treatment showed a lower GluCer level than those not 
being treated. Although plasmatic chitotriosidase level 
is a good biomarker of GD, GD patients with deficient 
TABLE I - Concentration of GluCer in plasma of GD patients with and without ERT, compared to normal individuals
Groups GluCer 
(µg/600 µL plasma)
GluCer 
(mmol/L plasma)
GluCer 
(ng/mg protein)
Normal (n = 5) 0.03 ± 0.03* 0.07 ± 0.07* 0.67 ± 0.78*
GD without treatment (n = 5) 0.57 ± 0.24 1.59 ± 0.27 13.7 ± 1.25
GD with ERT (n = 5) 0.05 ± 0.02* 0.11 ± 0.04* 1.23 ± 0.68*
Results expressed as mean ± SD (n = 5).
* Statistically different from GD without treatment group, p<0.001 by ANOVA followed by Tukey’s test.
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chitotriosidase activity have been reported in the literature 
(Guo et al., 1995). In such patients, GluCer quantification 
gains considerable importance. GluCer levels can be used 
both as an auxiliary diagnosis method for GD and as a 
treatment monitoring parameter. 
Our experiments with primary rabbit anti-bodies 
for human anti-glucosylceramide indicate that the bands 
observed in the chromatography in fact belong to GluCer 
(Figure 3B). After several repetitions of extraction, purifi-
cation and quantification steps with one sample, the same 
results were obtained, demonstrating the reproducibility 
of the techniques. 
CONCLUSIONS
In our study, we developed a methodology to extract, 
purify and quantify GluCer in plasma from GD patients, 
and to distinguish values considered pathological from 
those deemed normal. Also, the technique enables measu-
rement of the reduction in the concentration of glucosyl-
ceramide in response to ERT. Therefore, the evaluation of 
GluCer concentration in symptomatic and asymptomatic 
GD patients could be used in complementary diagnosis 
and as a means of monitoring the treatment. Our method 
appeared to be advantageous over earlier thin layer appro-
aches used in the quantification of GluCer. 
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